date,title,source
Oct-24-18,OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions,PR Newswire
Oct-29-18,OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer,PR Newswire
Nov-05-18,OncoSec to Host Conference Call to Review Preliminary KEYNOTE-695 Data,PR Newswire
Nov-07-18,OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial,PR Newswire
Nov-07-18,Todays Research Reports on Stocks to Watch: Vericel and OncoSec Medical,ACCESSWIRE
Nov-08-18,OncoSec Appoints Robert Ward to its Board of Directors,PR Newswire
Nov-20-18,OncoSec to Present at Piper Jaffray 30th Annual Healthcare Conference,PR Newswire
Nov-29-18,OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO Induces Abscopal Responses In Metastatic Melanoma Patients,PR Newswire
Dec-03-18,Analysts Expect Breakeven For OncoSec Medical Incorporated (NASDAQ:ONCS),Simply Wall St.
